TRC105 for Recurrent Glioblastoma
- Glioblastoma is an aggressive type of brain cancer that often resists treatment. TRC105 is an experimental drug that blocks the growth of new blood vessels. It is being studied for possible use in treating different kinds of cancer. Researchers want to see if TRC105 can be used to treat glioblastoma that has not responded to standard treatments.
- To test the safety and effectiveness of TRC105 in adults who have glioblastoma that has not responded to standard treatments.
- Individuals at least 18 years of age who have glioblastoma that has not responded to standard treatments.
- Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and other tests will be used to study the tumor before the start of treatment.
- Participants will have 28-day (4-week) cycles of treatment.
- Participants will have TRC105 intravenously once a week. The first infusion will take about 4 hours. The length of time needed for the infusion may be slowly reduced if it is well tolerated.
- At the end of the first cycle (the first 4 weeks), the imaging studies will be repeated before continuing TRC105.
- Participants will take TRC105 for as long as the tumor does not grow and the side effects are not too severe. They will have imaging studies at the end of every cycle to evaluate the tumor.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase 2 Study of TRC105 in Patients With Recurrent Glioblastoma (GBM)|
- To determine the radiographic response rate for patients with recurrent GBM treated with TRC105. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- To establish data regarding the anti-tumor activity of TRC105 in patients with GBM, as determined by progression free survival. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- To obtain information regarding the safety of TRC105 in patients with recurrent GBM. [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
|Study Start Date:||December 2012|
|Study Completion Date:||February 2014|
|Primary Completion Date:||February 2014 (Final data collection date for primary outcome measure)|
- TRC105 is an anti-angiogenic monoclonal antibody (mAb) that binds to CD105, a transmembrane glycoprotein that is essential for angiogenesis, and expressed abundantly on activated vascular endothelial cells (ECs). CD105 is a member of the transforming growth factor-Beta (TGF-Beta) receptor superfamily, and modulates TGF-Beta signaling leading to EC proliferation and migration.
- Immunohistochemistry studies reveal that CD105 is preferentially expressed in blood vessels of tumor tissues as compared with normal mucosa. For patients with GBM, increased expression of CD105 may correspond to worse survival times. Furthermore, expression of CD105 is essential for neovascularization, and is upregulated in the setting of VEGF inhibition.
- TRC105 binding to CD105 leads to inhibition of EC proliferation, neovascularization, and induces cell death via apoptosis. TRC105 may also mediate antibody-dependent cellular cytotoxicity (ADCC).
- To determine the radiographic response rate for patients with recurrent GBM treated with TRC105.
- To establish data regarding the anti-tumor activity of TRC105 in patients with GBM, as determined by progression free survival.
- To obtain information regarding the safety of TRC105 in patients with recurrent GBM.
- To evaluate the health-related quality of life (HRQL) in patients while on treatment with TRC105.
- To examine the effect of TRC105 on vascular permeability as measured by percent change from baseline in Ktrans of DCE-MRI.
- To examine the effect of TRC105 on vascular perfusion as measured by percent change from baseline in CBV, CBF, and MTT of DSC-MRI.
- To examine the effect of TRC105 on water diffusion as measured by percent change from baseline in ADC and FA of diffusion MRI.
- To examine the effect of TRC105 on tumor metabolism as measured by percent change from baseline in FDG uptake of PET scan.
- To obtain preliminary data regarding how changes in serial FDG-PET scans and physiological MRI correlate with radiographic response rates and with progression free survival in patients treated with TRC105.
-This is a phase II trial in patients with recurrent GBM who are VEGF therapy naive.
-Prior to treatment start, patients will undergo a magnetic resonance imaging (MRI) including MRI perfusion and diffusion scans, as well as an FDG-PET scan. Patients will then receive TRC105 as a single agent (weekly dose of 10 mg/kg IV). A cycle will consist of 4 weeks of therapy. At the end of the first cycle, the MR imaging and FDG-PET scans will be repeated before continuing treatment. Patients who are clinically and neurologically stable, and who have radiographic stable or responding disease at the end of each cycle will continue treatment with TRC105. MRI perfusion and diffusion will be repeated after the completion of each cycle of therapy.
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Joohee Sul, M.D.||National Cancer Institute (NCI)|